• OTS
  • February 29, 2020
SHARE
Post Views: 976

Sakamuri S, Eltepu L, Liu D, Lam S, Meade BR, Liu B, Dello Iacono G, Kabakibi A, Luukkonen L, Leedom T, Foster M, Bradshaw CW.
Chembiochem. 2019 Dec 21.

PubMed

Related articles

Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy

Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy

April 23rd, 2021
Non-specific interactions of antibody-oligonucleotide conjugates with living cells

Non-specific interactions of antibody-oligonucleotide conjugates with living cells

April 23rd, 2021
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

April 23rd, 2021
siRNAs containing 2′-fluorinated Northern-methanocarbacyclic (2′-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2′-F-NMC NTPs

siRNAs containing 2′-fluorinated Northern-methanocarbacyclic (2′-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2′-F-NMC NTPs

March 15th, 2021
Perspectives on the Designation of Oligonucleotide Starting Materials

Perspectives on the Designation of Oligonucleotide Starting Materials

March 15th, 2021
Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs.

Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs.

March 15th, 2021